ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028
MARKET OUTLOOK
Triton’s research report on the Asia-Pacific pharmaceutical continuous manufacturing market estimates the market to extend at a CAGR of 11.11% through the years 2021-2028. India, ASEAN countries, Japan, Australia & New Zealand, China, South Korea, and Rest of APAC form the market in this region.
In South Korea, several pharmaceutical companies have been thriving to enhance their R&D productivity and effectiveness. Moreover, the pharma sector’s growth is primarily motivated by the professional R&D human resources, along with the strategic nationwide collaboration network among industry, public research institutions, and academic organizations. This has resulted in the emergence of South Korea as an emerging contributor to healthcare innovations. Thus, such developments are likely to influence the demand for continuous manufacturing, in turn, boosting the pharmaceutical continuous manufacturing market across South Korea.
Furthermore, GEA experts in 2020 discussed the advantages of continuous pharmaceutical manufacturing, along with the advantages of recognizing its market in South Korea. This is another factor that is motivating the pharmaceutical continuous manufacturing market’s development in South Korea.
In Australia & New Zealand, rising pharmaceutical product spending is likely to significantly augment the pharmaceutical continuous manufacturing market. Additionally. the current continuous manufacturing approvals are focused on solid dose tablet manufacturing. Although, there is a surging momentum for active pharmaceutical ingredients and biologics, which is predicted to contribute to the development of the pharmaceutical continuous manufacturing market across Australia & New Zealand in the upcoming years.
COMPETITIVE OUTLOOK
Some of the well-known companies present in the market consist of Syntegon, Siemens Healthineers, Thermofisher Scientific Inc, Hosokawa Micron Corporation, Glatt GmbH, and Coperion GmbH.
- 1. ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET - SUMMARY
- 2. INDUSTRY OUTLOOK
- 2.1. PORTER’S FIVE FORCES MODEL
- 2.1.1. THREAT OF NEW ENTRANTS
- 2.1.2. THREAT OF SUBSTITUTE PRODUCTS
- 2.1.3. BARGAINING POWER OF BUYERS
- 2.1.4. BARGAINING POWER OF SUPPLIERS
- 2.1.5. COMPETITIVE RIVALRY
- 2.2. IMPACT OF COVID-19 ON PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET
- 2.3. LEGAL, POLICY, & REGULATORY FRAMEWORK
- 2.4. MARKET ATTRACTIVENESS INDEX
- 2.5. VENDOR SCORECARD
- 2.6. KEY INSIGHTS
- 2.7. MARKET DRIVERS
- 2.7.1. RISE IN INITIATIVES BY REGULATORY AUTHORITIES FOR THE ADOPTION OF CONTINUOUS MANUFACTURING
- 2.7.2. SURGING ACCEPTANCE OF PHARMACEUTICAL CONTINUOUS MANUFACTURING SYSTEMS
- 2.7.3. RISING HEALTHCARE EXPENDITURE
- 2.8. MARKET RESTRAINTS
- 2.8.1. LACK OF DEMAND FOR PCM SYSTEMS IN UNDERDEVELOPED ECONOMIES
- 2.8.2. RISING CUSTOMER EXPECTATIONS FOR BETTER MEDICINES
- 2.9. MARKET OPPORTUNITIES
- 2.9.1. INCREASING OPPORTUNITIES IN THE UNTAPPED EMERGING ECONOMIES
- 2.9.2. SURGE IN THE MANUFACTURING OF LARGE MOLECULES AND BIOLOGICS
- 3. ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET OUTLOOK - BY PRODUCT
- 3.1. INTEGRATED CONTINUOUS SYSTEM
- 3.2. SEMI-CONTINUOUS SYSTEM
- 3.3. CONTROL & SOFTWARE
- 4. ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET OUTLOOK - BY APPLICATION
- 4.1. FINAL DRUG PRODUCT MANUFACTURING
- 4.2. API MANUFACTURING
- 5. ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET OUTLOOK - BY END-USER
- 5.1. PHARMACEUTICAL COMPANIES
- 5.2. CONTRACT MANUFACTURING ORGANIZATIONS
- 5.3. OTHER END-USERS
- 6. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET - ASIA-PACIFIC
- 6.1. COUNTRY ANALYSIS
- 6.1.1. CHINA
- 6.1.2. INDIA
- 6.1.3. JAPAN
- 6.1.4. AUSTRALIA & NEW ZEALAND
- 6.1.5. SOUTH KOREA
- 6.1.6. ASEAN COUNTRIES
- 6.1.7. REST OF ASIA-PACIFIC
- 7. COMPANY PROFILE
- 7.1. HOSOKAWA MICRON CORPORATION
- 7.2. GEA GROUP AG
- 7.3. LB BOHLE MASCHINEN + VERFAHREN GMBH
- 7.4. THERMOFISHER SCIENTIFIC INC
- 7.5. SIEMENS HEALTHINEERS
- 7.6. ELI LILLY & COMPANY
- 7.7. PFIZER INC
- 7.8. GLATT GMBH
- 7.9. SYNTEGON (FORMERLY BOSCH PACKAGING TECHNOLOGY)
- 7.10. GEBRUDER LODIGE MASCHINENBAU GMBH
- 7.11. KORSCH AG
- 7.12. COPERION GMBH
- 7.13. MUNSON MACHINERY COMPANY
- 8. RESEARCH METHODOLOGY & SCOPE
- 8.1. RESEARCH SCOPE & DELIVERABLES
- 8.1.1. OBJECTIVES OF STUDY
- 8.1.2. SCOPE OF STUDY
- 8.2. SOURCES OF DATA
- 8.2.1. PRIMARY DATA SOURCES
- 8.2.2. SECONDARY DATA SOURCES
- 8.3. RESEARCH METHODOLOGY
- 8.3.1. EVALUATION OF PROPOSED MARKET
- 8.3.2. IDENTIFICATION OF DATA SOURCES
- 8.3.3. ASSESSMENT OF MARKET DETERMINANTS
- 8.3.4. DATA COLLECTION
- 8.3.5. DATA VALIDATION & ANALYSIS
- LIST OF TABLES
- TABLE 1: ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (IN $ MILLION)
- TABLE 2: ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2021-2028 (IN $ MILLION)
- TABLE 3: ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (IN $ MILLION)
- TABLE 4: ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END-USER, 2021-2028 (IN $ MILLION)
- TABLE 5: ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (IN $ MILLION)
- LIST OF FIGURES
- FIGURE 1: ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
- FIGURE 2: ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY INTEGRATED CONTINUOUS SYSTEM, 2021-2028 (IN $ MILLION)
- FIGURE 3: ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY SEMI-CONTINUOUS SYSTEM, 2021-2028 (IN $ MILLION)
- FIGURE 4: ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY CONTROL & SOFTWARE, 2021-2028 (IN $ MILLION)
- FIGURE 5: ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY FINAL DRUG PRODUCT MANUFACTURING, 2021-2028 (IN $ MILLION)
- FIGURE 6: ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY API MANUFACTURING, 2021-2028 (IN $ MILLION)
- FIGURE 7: ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PHARMACEUTICAL COMPANIES, 2021-2028 (IN $ MILLION)
- FIGURE 8: ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY CONTRACT MANUFACTURING ORGANIZATIONS, 2021-2028 (IN $ MILLION)
- FIGURE 9: ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY OTHER END-USERS, 2021-2028 (IN $ MILLION)
- FIGURE 10: CHINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
- FIGURE 11: INDIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
- FIGURE 12: JAPAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
- FIGURE 13: AUSTRALIA & NEW ZEALAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
- FIGURE 14: SOUTH KOREA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
- FIGURE 15: ASEAN COUNTRIES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
- FIGURE 16: REST OF ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)